- Home
- ESGL vs LCTX Comparison
ESGL vs LCTX Comparison
Compare ESGL & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESGL
- LCTX
- Stock Information
- Founded
- ESGL 1999
- LCTX 1990
- Country
- ESGL Singapore
- LCTX United States
- Employees
- ESGL N/A
- LCTX N/A
- Industry
- ESGL
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ESGL
- LCTX Health Care
- Exchange
- ESGL Nasdaq
- LCTX Nasdaq
- Market Cap
- ESGL 114.8M
- LCTX 107.3M
- IPO Year
- ESGL N/A
- LCTX N/A
- Fundamental
- Price
- ESGL $2.96
- LCTX $0.90
- Analyst Decision
- ESGL
- LCTX Strong Buy
- Analyst Count
- ESGL 0
- LCTX 5
- Target Price
- ESGL N/A
- LCTX $4.20
- AVG Volume (30 Days)
- ESGL 61.5K
- LCTX 2.4M
- Earning Date
- ESGL 07-01-2025
- LCTX 08-07-2025
- Dividend Yield
- ESGL N/A
- LCTX N/A
- EPS Growth
- ESGL N/A
- LCTX N/A
- EPS
- ESGL N/A
- LCTX N/A
- Revenue
- ESGL $6,099,784.00
- LCTX $9,557,000.00
- Revenue This Year
- ESGL N/A
- LCTX N/A
- Revenue Next Year
- ESGL N/A
- LCTX $232.66
- P/E Ratio
- ESGL N/A
- LCTX N/A
- Revenue Growth
- ESGL N/A
- LCTX 19.42
- 52 Week Low
- ESGL $0.90
- LCTX $0.37
- 52 Week High
- ESGL $3.04
- LCTX $1.15
- Technical
- Relative Strength Index (RSI)
- ESGL 77.20
- LCTX 74.23
- Support Level
- ESGL $2.92
- LCTX $0.67
- Resistance Level
- ESGL $3.04
- LCTX $0.83
- Average True Range (ATR)
- ESGL 0.13
- LCTX 0.06
- MACD
- ESGL 0.03
- LCTX 0.02
- Stochastic Oscillator
- ESGL 88.83
- LCTX 84.94
About ESGL ESGL Holdings Limited
ESGL Holdings Ltd is a waste management, treatment, and recycling company involved in the collection and recycling of hazardous and non-hazardous industrial waste from customers such as pharmaceutical, semiconductor, petrochemical, and electroplating companies.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.